Abbott Laboratories Stock – Fundamental Analysis
Fundamental Data & Ratios (Balance sheet update: 3/10/2026)
| Balance Sheet | Total Assets | 86,713,000,000.00 | ROE | 60.12 % |
| Balance Sheet | Total Equity | 52,130,000,000.00 | ROA | 7.52 % |
| Cashflow | Capital Expenditures | -2,171,000,000.00 | P/FCF | 24.33 |
| Cashflow | Free Cash Flow | 7,394,999,808.00 | – | – |
| Cashflow | Operating Cash Flow | 9,566,000,000.00 | P/CF | 18.81 |
| Income | Earnings per Share (diluted) | 3.73 | Div. Yield | 2.33 % |
| Income | Net Income | 6,524,000,000.00 | P/E | 27.61 |
| Income | Shares Outstanding | 1,747,000,000.00 | P/B | 3.45 |
| Income | Total Revenue | 44,328,000,000.00 | P/S | 4.06 |
Ratios calculated on: 10/14/2026
Company Description
Abbott Laboratories (Abbott) is engaged in the discovery, development, manufacture, and sale of a portfolio of science-based health care products. Abbott operates in four business segments: diagnostics, medical devices, nutritionals and generic pharmaceuticals. Geographically, 30% of its revenue is generated in the United States; 30% in Western Europe, Canada, Japan and Australia, and 40% in the economies, including India, China, Russia and Brazil. In January 2013, the Company completed the separation of its research-based pharmaceuticals business, which became AbbVie, a new independent biopharmaceutical company. In August 2013, Abbott Laboratories completed its acquisition of OptiMedica Corporation. In August 2013, Abbott Laboratories completed its acquisition of IDEV Technologies.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.abbott.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more